Listed

Butterfly Network, Inc.: Form 10-Q for the period ended Sep 30, 2022

Filed with the SEC on Nov 3, 2022 and accepted by EDGAR at Nov 3, 2022, 17:09 ET.

Share

Management's discussion and analysis

As filed, 43,019 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our condensed consolidated results of operations and financial condition. The discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto contained in this Quarterly Report on Form 10-Q and the consolidated financial statements and notes thereto for the year ended December 31, 2021 contained in our Annual Report on Form 10-K for the year ended December 31, 2021, as amended. This discussion contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the “Risk Factors” sections of our Annual Report on Form 10-K for the year ended December 31, 2021, as amended, and of this Quarterly Report on Form 10-Q. Actual results may differ materially from those contained in any forward-looking statements. Unless the context otherwise requires, references to “we”, “us”, “our”, and “the Company” are intended to mean the business and operations of Butterfly Network, Inc. and its consolidated subsidiaries. The unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2022 and 2021, respectively, present the financial position and results of operations of Butterfly Network, Inc. and its wholly-owned subsidiaries.

Overview

We are an innovative digital health business transforming care with hand-held, whole-body ultrasound. Powered by our proprietary Ultrasound-on-Chip™ technology, our solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional’s pocket with a unique combination of cloud-connected software and hardware technology that is easily accessed through a mobile app.

Butterfly iQ+ is an ultrasound transducer that can perform whole-body imaging in a single handheld probe using semiconductor technology. Our Ultrasound-on-Chip™ makes ultrasound more accessible outside of large healthcare institutions, while our software is intended to make the product easy to use and fully integrated with the clinical workflow, accessible on a user’s smartphone, tablet and almost any hospital computer system connected to the Internet. Butterfly aims to enable the delivery of imaging information anywhere at point-of-care to drive earlier detection throughout the body and remote management of health conditions. We market and sell the Butterfly system, which includes probes and related accessories and software subscriptions, to healthcare systems, physicians and healthcare providers through a direct sales force, distributors and our eCommerce channel.

COVID-19

The COVID-19 pandemic that began in 2020 has created significant global economic uncertainty. Uncertainty remains regarding the extent, timing and duration of the pandemic, including the emergence of new strains of the virus that may be more contagious or virulent and the extent to which the availability of vaccines and other safety measures will positively impact public health conditions. The uncertainty and potential economic volatility impact our customer base, supply chains, business practices and employees.

The COVID-19 pandemic and its economic impact have caused financial strain on our customer base due to decreased funding and other revenue shortfalls. During the pandemic, we have seen our customer base become further strained in solving immediate problems associated with the variants. As a result, some of our customers have had to shift their attention to these pressing issues, resulting in longer sales cycles and slower adoption in the near term.

In addition, the issues originally brought on by COVID-19 continue to have an ongoing adverse impact on global supply chains, including ours. Although the impact of COVID-19 on our supply chains is lessening, we are still experiencing limited constraints in availability and increasing costs required to obtain some inventory components. However, the semiconductor chips used in our probes are manufactured under an inventory supply agreement and to date we have not experienced any constraints. We have and will continue to implement operating efficiencies in our supply chain and manufacturing processes to help offset the cost increases in component parts for our device. Additionally, our new products are being designed to avoid single sourced components to mitigate supply chain risk.

The pandemic caused us to make modifications to our business practices, including work from home policies, establishing strict health and safety protocols for our offices specific to COVID-19 and imposing restrictions on employee travel. Our employees have resumed traveling to perform sales-generating and corporate activities, and we have reopened our offices, allowing our employees to return.

We continue to closely monitor the developments of COVID-19 for any material impact on our business. Given the uncertainty and potential economic volatility of the impact of the COVID-19 pandemic, the developments we have experienced may change based on new information that may emerge concerning COVID-19, its economic impact on local, regional, national and international markets and the actions to contain it or address its impacts.

Key Performance Metrics

We review the key performance measures discussed below to evaluate the business and measure performance, identify trends, formulate plans and make strategic decisions. Our key performance metrics may fluctuate over time as the adoption of our devices increases which may shift the revenue mix more toward software and other services. The quarterly metrics may be impacted by the timing of device sales.

Units fulfilled

We define units fulfilled as the number of devices whereby control is transferred to a customer. We do not adjust this metric for returns as our volume of returns has historically been low. We view units fulfilled as a key indicator of the growth of our business. We believe that this metric is useful to investors because it presents our core growth and performance of our business period over period.

Units fulfilled increased by 148, or 2.7%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021, primarily due to increased device sales volume from our direct sales force and global health channels. The increases were partially offset by lower sales in our eCommerce channel.

Software and other services mix

We define software and other services mix as a percentage of our total revenue recognized in a reporting period that is based on software subscriptions and other related services, consisting primarily of our software as a service (“SaaS”) offering. We view software and other services mix as a key indicator of the profitability of our business, and thus we believe that this metric is useful to investors.

Software and other services mix increased by 7.1 percentage points, to 32.9% for the three months ended September 30, 2022 compared to the three months ended September 30, 2021. The increase was due to increases in software subscription renewals and an expansion of software subscription offerings. In addition, the increase is due to the timing of revenue recognition for our SaaS and other software subscription contracts as revenue from such contracts is deferred and recognized over the service period.

Non-GAAP Financial Measures

We present non-GAAP financial measures in order to assist readers of our condensed consolidated financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures, Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA, provide an additional tool for investors to use in comparing our financial performance over multiple periods.

Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA are key performance measures that our management uses to assess our operating performance. Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

Our Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA are not prepared in accordance with U.S. GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with U.S. GAAP. When evaluating our performance, you should consider Adjusted Gross Profit, Adjusted Gross Margin and Adjusted EBITDA alongside other financial performance measures prepared in accordance with U.S. GAAP, including gross profit, gross margin, operating loss and net loss.

Adjusted Gross Profit and Adjusted Gross Margin

We calculate Adjusted Gross Profit as gross profit adjusted to exclude depreciation and amortization, non-recurring changes to our warranty liability, non-recurring losses on product purchase commitments and non-recurring write-downs of inventories. We calculate Adjusted Gross Margin as gross margin adjusted to exclude depreciation and amortization, non-recurring changes to our warranty liability, losses on product purchase commitments and non-recurring write-downs of inventories.

Our changes in the warranty liability are excluded from Adjusted Gross Profit and Adjusted Gross Margin when they are outside the normal course of operations for our business. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs.

We also exclude from Adjusted Gross Profit and Adjusted Gross Margin non-recurring losses on product purchase commitments and non-recurring write-downs of inventories when they are outside the normal course of business and in the period the expenses are incurred. The non-recurring losses on product purchase commitments relate to inventory supply agreements where the expected losses exceed the benefit of the contracts, and the non-recurring write-downs of inventories adjustments are for excess and obsolete inventory resulting from a shift in product lines.

The following table reconciles gross profit to Adjusted Gross Profit and gross margin to Adjusted Gross Margin, the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.

(In thousands)

​ ​ ​ ​ ​ ​ ​ Three months ended September 30, 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Nine months ended September 30, 2022 ​ ​ ​ ​ 2021
Revenue $19,618 ​ $14,621 ​ $54,407 ​ $43,578
Cost of revenue ​ 8,629 ​ 19,743 ​ 24,503 ​ 34,064
Gross profit (loss) ​ $10,989 ​ $(5,122) ​ $29,904 ​ $9,514
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Gross margin ​ ​ 56.0% ​ ​ (35.0)% ​ ​ 55.0% ​ ​ 21.8%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Add: ​ ​ ​ ​
Depreciation and amortization ​ 1,019 ​ 131 ​ 2,122 ​ 291
Warranty liability policy change ​ ​ — ​ ​ — ​ ​ — ​ ​ (560)
Loss on purchase commitments ​ — ​ ​ 11,623 ​ — ​ 11,623
Inventory write-downs ​ — ​ ​ 582 ​ — ​ 582
Adjusted gross profit ​ $12,008 ​ $7,214 ​ $32,026 ​ $21,450
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Adjusted gross margin ​ ​ 61.2% ​ ​ 49.3% ​ ​ 58.9% ​ ​ 49.2%

Adjusted EBITDA

We calculate Adjusted EBITDA as net loss adjusted to exclude interest income, interest expense, changes in the fair value of warrant liabilities, other expense, net, provision for income taxes, stock based compensation, depreciation and amortization and other non-recurring items. The other non-recurring items include costs related to our executive transition, adjustments for the warranty liability policy changes, discretionary transaction bonuses and other fees incurred with the close of the Business Combination, non-recurring losses on purchase commitments, non-recurring inventory write-downs and non-recurring reduction in force related severance and benefits costs.

Our non-recurring discretionary bonuses are excluded from Adjusted EBITDA when they are outside the normal course of operations for our business and were given at the discretion of management due to the completion of the Business Combination. The non-recurring costs related to the executive transition include one-time severance and bonus payments and the recruiting expenses for our current CEO. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs. The non-recurring losses on purchase commitments relate to inventory supply agreements where the expected losses exceed the benefit of the contracts, and the non-recurring inventory write-down adjustments were for excess and obsolete inventory resulting from a shift in product lines. The non-recurring reduction in force related severance and benefits costs are employee-related costs incurred in relation to the Company’s reduction in force in the third quarter of 2022.

The following table reconciles net loss to Adjusted EBITDA, the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP.

(In thousands)

​ ​ ​ ​ ​ ​ ​ Three months ended September 30, 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Nine months ended September 30, 2022 ​ ​ ​ ​ 2021 ​ ​ ​
Net loss $(54,742) $(13,561) $(135,020) $(17,193) ​
Interest income ​ (1,304) ​ (893) ​ (1,574) ​ (1,739) ​
Interest expense ​ 2 ​ — ​ 2 ​ 645 ​
Change in fair value of warrant liabilities ​ ​ 9,087 ​ ​ (42,958) ​ ​ (8,881) ​ ​ (130,528) ​
Other expense, net ​ 898 ​ 428 ​ 1,387 ​ 1,320 ​
Provision for income taxes ​ 27 ​ (3) ​ 68 ​ 72 ​
Stock based compensation ​ 9,413 ​ 10,734 ​ 27,428 ​ 38,769 ​
Depreciation and amortization ​ 1,875 ​ 505 ​ 4,066 ​ 1,420 ​
CEO transition costs ​ ​ — ​ ​ — ​ ​ — ​ ​ 5,398 ​
Warranty liability policy change ​ ​ — ​ ​ — ​ ​ — ​ ​ (560) ​
Transaction bonus ​ ​ — ​ ​ — ​ ​ — ​ ​ 1,653 ​
Loss on purchase commitments ​ — ​ ​ 11,623 ​ — ​ 11,623 ​
Inventory write-downs ​ — ​ ​ 582 ​ — ​ 582 ​
Reduction in force related severance and benefits ​ ​ 1,830 ​ ​ — ​ ​ 1,830 ​ ​ — ​
Adjusted EBITDA $(32,914) $(33,543) $(110,694) $(88,538) ​

Description of Certain Components of Financial Data

Revenue

Revenue consists of revenue from the sale of products, such as medical devices and accessories, and the sale of software and related services, classified as software and other services revenue on our condensed consolidated statements of operations and comprehensive loss, which are SaaS subscriptions and product support and maintenance (“Support”). SaaS subscriptions include licenses for teams and individuals as well as enterprise level subscriptions. For sales of products, revenue is recognized at a point in time upon transfer of control to the customer. SaaS subscriptions and Support are generally related to stand-ready obligations and are recognized ratably over time.

Over time as the adoption of our devices increases through further market penetration and as practitioners in the Butterfly network continue to use our devices, we expect our annual revenue mix to shift more toward software and other services. The quarterly revenue mix may be impacted by the timing of device sales.

To date, we have invested heavily in building out our direct salesforce and plan to continue to do so, with the ultimate goal of growing adoption at large scale healthcare systems. As we expand our healthcare system software offerings and develop relationships with larger health systems, we continue to expect a higher proportion of our sales in health systems compared to eCommerce.

Cost of revenue

Cost of product revenue consists of product costs including manufacturing costs, personnel costs and benefits, inbound freight, packaging, warranty replacement costs, payment processing fees and inventory obsolescence and write-offs. We expect our cost of product revenue to fluctuate over time due to the level of units fulfilled in any given period and fluctuate as a percentage of product revenue over time as our focus on operational efficiencies in our supply chain may be offset by increased prices of certain inventory components.

Cost of software and other services revenue consists of personnel costs, cloud hosting costs and payment processing fees. Because the costs and associated expenses to deliver our SaaS offerings are less than the costs and associated expenses of manufacturing and selling our device, we anticipate an improvement in profitability and margin expansion over time as our revenue mix shifts increasingly towards software and other services. We plan to continue to invest additional resources to expand and further develop our SaaS and other service offerings.

Also included in cost of revenue are losses on product purchase commitments relating to inventory supply agreements where the expected losses exceed the benefit of the contracts. We consider a variety of factors and data points when determining the existence and scope of a loss for the minimum purchase commitment. The factors and data points include Company-specific forecasts which are reliant on our limited sales history, agreement-specific provisions, macroeconomic factors and market and industry trends. Determining the loss is subjective and requires significant management judgment and estimates.

Research and development (R&D)

Research and development expenses primarily consist of personnel costs and benefits, facilities-related expenses, depreciation expense, consulting and professional fees, fabrication services, software and other outsourcing expenses. Most of our research and development expenses are related to developing new products and services, which we define as not having reached the point of commercialization and improving our products and services that have been commercialized. Consulting expenses are related to general development activities and clinical/regulatory research. Fabrication services include certain third-party engineering costs, product testing and test boards. Research and development expenses are expensed as incurred. We expect to continue to make substantial investments in our product development, clinical and regulatory capabilities.

Sales and marketing

Sales and marketing expenses primarily consist of personnel costs and benefits, third party logistics, fulfillment and outbound shipping costs, advertising, promotional costs, conferences and events and related facilities and information technology costs. We expect to continue to make substantial investments in our sales capabilities.

General and administrative

General and administrative expenses primarily consist of personnel costs and benefits, insurance, patent fees, software costs, facilities costs and outside services. Outside services consist of professional services, legal and other professional fees.

Results of Operations

We operate as a single reportable segment to reflect the way our Chief Operating Decision Maker reviews and assesses the performance of the business. The accounting policies are described in Note 2 “Summary of Significant Accounting Policies” in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

(in thousands)

​ ​ ​ ​ Revenue: ​ ​ ​ ​ ​ ​ ​ Three months ended September 30, 2022 ​ ​ Dollars ​ ​ ​ ​ ​ ​ % of ​ revenue ​ ​ ​ ​ ​ ​ ​ 2021 ​ ​ Dollars ​ ​ ​ ​ ​ % of revenue ​ ​ ​ ​ ​ ​ ​ Nine months ended September 30, 2022 ​ ​ Dollars ​ ​ ​ ​ ​ ​ % of ​ revenue ​ ​ ​ ​ ​ ​ ​ 2021 ​ ​ Dollars ​ ​ ​ ​ ​ ​ % of revenue
Product ​ $13,164 67.1% ​ $10,848 74.2% ​ $37,607 69.1% ​ $33,455 76.8%
Software and other services ​ ​ 6,454 32.9% ​ ​ 3,773 25.8% ​ ​ 16,800 30.9% ​ ​ 10,123 23.2%
Total revenue: ​ $19,618 100.0% ​ $14,621 100.0% ​ $54,407 100.0% ​ $43,578 100.0%
Cost of revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Product ​ ​ 6,534 33.3% ​ ​ 7,584 51.9% ​ ​ 19,481 35.8% ​ ​ 21,090 48.4%
Software and other services ​ ​ 2,095 10.7% ​ ​ 536 3.7% ​ ​ 5,022 9.2% ​ ​ 1,351 3.1%
Loss on product purchase commitments ​ ​ — ​ —% ​ ​ 11,623 ​ 79.5% ​ ​ — ​ —% ​ ​ 11,623 ​ 26.7%
Total cost of revenue: ​ $8,629 44.0% ​ $19,743 135.0% ​ $24,503 45.0% ​ $34,064 78.2%
Gross profit ​ $10,989 56.0% ​ $(5,122) (35.0)% ​ $29,904 55.0% ​ $9,514 21.8%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Research and development ​ ​ 23,154 118.0% ​ ​ 21,654 148.1% ​ ​ 69,997 128.7% ​ ​ 54,459 125.0%
Sales and marketing ​ ​ 15,811 80.6% ​ ​ 14,203 97.1% ​ ​ 47,451 87.2% ​ ​ 34,550 79.3%
General and administrative ​ ​ 18,056 92.0% ​ ​ 16,008 109.5% ​ ​ 56,474 103.8% ​ ​ 67,928 155.9%
Total operating expenses ​ $57,021 290.7% ​ $51,865 354.7% ​ $173,922 319.7% ​ $156,937 360.1%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Loss from operations ​ $(46,032) (234.6)% ​ $(56,987) (389.8)% ​ $(144,018) (264.7)% ​ $(147,423) (338.3)%
Interest income ​ ​ 1,304 6.6% ​ ​ 893 6.1% ​ ​ 1,574 2.9% ​ ​ 1,739 4.0%
Interest expense ​ ​ (2) (0.0)% ​ ​ — —% ​ ​ (2) (0.0)% ​ ​ (645) (1.5)%
Change in fair value of warrant liabilities ​ ​ (9,087) ​ (46.3)% ​ ​ 42,958 ​ 293.8% ​ ​ 8,881 ​ 16.3% ​ ​ 130,528 ​ 299.5%
Other income (expense), net ​ ​ (898) (4.6)% ​ ​ (428) (2.9)% ​ ​ (1,387) (2.5)% ​ ​ (1,320) (3.0)%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Loss before provision for income taxes ​ $(54,715) (278.9)% ​ $(13,564) (92.8)% ​ $(134,952) (248.0)% ​ $(17,121) (39.3)%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Provision for income taxes ​ ​ 27 0.1% ​ ​ (3) (0.0)% ​ ​ 68 0.1% ​ ​ 72 0.2%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Net loss ​ $(54,742) (279.0)% ​ $(13,561) (92.8)% ​ $(135,020) (248.2)% ​ $(17,193) (39.5)%

Comparison of the three months ended September 30, 2022 and 2021

Revenue

(in thousands)

​ ​ Revenue: ​ ​ ​ ​ ​ Three months ended September 30, 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ Change ​ ​ ​ ​ ​ ​ ​ % Change ​
Product $13,164 ​ $10,848 ​ $2,316 21.3%
Software and other services ​ 6,454 ​ ​ 3,773 ​ ​ 2,681 71.1%
Total revenue: ​ $19,618 ​ $14,621 ​ $4,997 34.2%

Product revenue increased by $2.3 million, or 21.3%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021. The increase in product revenue was primarily driven by higher prices of products sold due to a price increase at the end of the third quarter of 2021. We also saw an increase in volume in our global health and health systems channels that was partially offset by lower volume in our eCommerce and veterinary channels.

Software and other services revenue increased by $2.7 million, or 71.1%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021. The increase was driven by a higher volume of our SaaS subscriptions sold in conjunction with sales of our devices, as well as the current year subscription renewals.

Cost of revenue

(in thousands)

​ ​ Cost of revenue: ​ ​ ​ ​ ​ ​ Three months ended September 30, 2022 ​ ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ Change ​ ​ ​ ​ ​ ​ ​ % Change ​
Product $6,534 ​ $7,584 ​ $(1,050) (13.8)%
Software and other services ​ 2,095 ​ ​ 536 ​ ​ 1,559 290.9%
Loss on product purchase commitments ​ ​ — ​ ​ 11,623 ​ ​ (11,623) (100.0)%
Total cost of revenue: ​ $8,629 ​ $19,743 ​ $(11,114) (56.3)%
Percentage of revenue ​ 44.0% 135.0% ​

Cost of product revenue decreased by $1.1 million, or 13.8%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021. This decrease was primarily driven by our second-generation device, the Butterfly iQ+, being less costly to produce due to operational efficiencies, partially offset by increased prices of certain inventory components.

Cost of software and other services revenue increased by $1.6 million, or 290.9%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021. This increase was primarily driven by higher headcount that supports our software and other services products and increases in cloud hosting costs and amortization expenses.

Loss on product purchase commitments decreased by $11.6 million, or 100.0%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021 due to the non-recurrence of such losses in 2022.

Research and development

(in thousands)

​ ​ ​ ​ ​ ​ ​ ​ Three months ended September 30, 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Change ​ ​ ​ ​ ​ ​ % Change
Research and development $23,154 $21,654 $1,500 6.9%
Percentage of revenue ​ 118.0% 148.1% ​

Research and development expenses increased by $1.5 million, or 6.9%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021. This increase was primarily driven by higher product development supplies costs of $0.9 million, software costs of $0.4 million and non-recurring reduction in force related severance and benefits costs of $1.1 million, partially offset by lower recurring personnel costs of $0.8 million.

Sales and marketing

(in thousands)

​ ​ ​ ​ ​ ​ ​ ​ Three months ended September 30, 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Change ​ ​ ​ ​ ​ ​ % Change
Sales and marketing $15,811 $14,203 $1,608 11.3%
Percentage of revenue ​ 80.6% 97.1% ​

Sales and marketing expenses increased by $1.6 million, or 11.3%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021. This increase was primarily driven by higher personnel costs of $1.5 million, including non-recurring reduction in force related severance and benefits costs of $0.3 million, and depreciation and amortization expenses of $0.5 million, partially offset by lower marketing costs of $0.8 million.

General and administrative

(in thousands)

​ ​ ​ ​ ​ ​ ​ ​ Three months ended September 30, 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Change ​ ​ ​ ​ ​ ​ % Change
General and administrative $18,056 $16,008 $2,048 12.8%
Percentage of revenue ​ 92.0% 109.5% ​

General and administrative expenses increased by $2.0 million, or 12.8%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021. This increase was primarily due to higher personnel costs of

$1.3 million, including non-recurring reduction in force related severance and benefits costs of $0.4 million, depreciation and amortization expenses of $0.6 million and professional service fees of $0.5 million, partially offset by lower recruiting expenses of $0.6 million.

Comparison of the nine months ended September 30, 2022 and 2021

Revenue

(in thousands)

​ ​ Revenue: ​ ​ ​ ​ ​ Nine months ended September 30, 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ Change ​ ​ ​ ​ ​ ​ ​ % Change ​
Product $37,607 ​ $33,455 ​ $4,152 12.4%
Software and other services ​ 16,800 ​ ​ 10,123 ​ ​ 6,677 66.0%
Total revenue: ​ $54,407 ​ $43,578 ​ $10,829 24.8%

Product revenue increased by $4.2 million, or 12.4%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. The increase in product revenue was primarily driven by higher prices of products sold due to a price increase in the third quarter of 2021 as well as increased sales volumes in our health systems, distributor and veterinary channels, partially offset by lower volumes in our eCommerce channel.

Software and other services revenue increased by $6.7 million, or 66.0%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. The increase was driven by a higher volume of our SaaS subscriptions sold in conjunction with sales of our devices, as well as the current year subscription renewals.

Cost of revenue

(in thousands)

​ ​ Cost of revenue: ​ ​ ​ ​ ​ ​ Nine months ended September 30, 2022 ​ ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ Change ​ ​ ​ ​ ​ ​ ​ % Change ​
Product $19,481 ​ $21,090 ​ $(1,609) (7.6)%
Software and other services ​ 5,022 ​ ​ 1,351 ​ ​ 3,671 271.7%
Loss on product purchase commitments ​ ​ — ​ ​ 11,623 ​ ​ (11,623) ​ (100.0)%
Total cost of revenue: ​ $24,503 ​ $34,064 ​ $(9,561) (28.1)%
Percentage of revenue ​ 45.0% 78.2% ​

Cost of product revenue decreased by $1.6 million, or 7.6%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. This decrease was primarily driven by a higher mix of sales of our second-generation device, the Butterfly iQ+, which is less costly to produce due to operational efficiencies, partially offset by increased prices of certain inventory components, a higher volume of accessories sold and $0.6 million of higher warranty expense due to a one-time benefit in the prior year from a change in our warranty liability policy.

Cost of software and other services revenue increased by $3.7 million, or 271.7%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. This increase was primarily driven by higher headcount that supports our software and other services products and increases in cloud hosting costs and amortization expenses.

Loss on product purchase commitments decreased by $11.6 million, or 100.0%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 due to the non-recurrence of such losses in 2022.

Research and development

(in thousands)

​ ​ ​ ​ ​ ​ ​ ​ Nine months ended September 30, 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Change ​ ​ ​ ​ ​ ​ % Change
Research and development $69,997 $54,459 $15,538 28.5%
Percentage of revenue ​ 128.7% 125.0% ​

28

Research and development expenses increased by $15.5 million, or 28.5%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. This increase was primarily driven by higher personnel costs of $9.5 million, including higher stock-based compensation expense of $3.1 million and non-recurring reduction in force related severance and benefits costs of $1.1 million, software costs of $1.9 million, product development supplies costs of $1.8 million, facilities-related costs of $1.5 million and professional service fees of $1.2 million.

Sales and marketing

(in thousands)

​ ​ ​ ​ ​ ​ ​ ​ Nine months ended September 30, 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Change ​ ​ ​ ​ ​ ​ % Change
Sales and marketing $47,451 $34,550 $12,901 37.3%
Percentage of revenue ​ 87.2% 79.3% ​

Sales and marketing expenses increased by $12.9 million, or 37.3%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. This increase was primarily driven by higher personnel costs of $9.2 million, including non-recurring reduction in force related severance and benefits costs of $0.3 million, travel and entertainment costs of $1.8 million, facilities-related costs of $1.2 million and software and computer supplies costs of $0.6 million.

General and administrative

(in thousands)

​ ​ ​ ​ ​ ​ ​ ​ Nine months ended September 30, 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Change ​ ​ ​ ​ ​ ​ % Change
General and administrative $56,474 $67,928 $(11,454) (16.9)%
Percentage of revenue ​ 103.8% 155.9% ​

General and administrative expenses decreased by $11.5 million, or 16.9%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. This decrease was primarily due to lower personnel costs of $9.0 million, driven by a reduction in stock-based compensation expense of $14.1 million from the non-recurrence of certain stock awards vesting upon the closing of the Business Combination in the prior year and partially offset by non-recurring reduction in force related severance and benefits costs of $0.4 million, lower recruiting expenses of $2.9 million from the non-recurrence of certain costs associated with our CEO transition, and lower professional service fees of $1.5 million. The decrease was partially offset by higher depreciation and amortization expenses of $1.3 million and insurance-related expenses of $0.5 million.

Liquidity and Capital Resources

Since our inception, our primary sources of liquidity are cash flows from operations, proceeds from the Business Combination and issuances of preferred stock and convertible notes. Our primary uses of liquidity are operating expenses, working capital requirements and capital expenditures. Cash flows from operations have been historically negative as we continue to develop new products and services and increase our sales and marketing efforts. We expect to be cash flow negative on an annual basis, although we may have quarterly results where cash flows from operations are positive.

We expect that our existing cash and cash flows from operations will be sufficient to meet our liquidity, capital expenditure, and anticipated working capital requirements and fund our operations for at least the next 12 months.

Our cash and cash equivalents and investments in marketable securities balance as of September 30, 2022 was $267.9 million. Our future capital requirements may vary from those currently planned and will depend on various factors, including our rate of revenue growth and the timing and extent of spending on strategic business initiatives.

We have restricted cash of $4.0 million as of September 30, 2022 to secure a letter of credit for one of our leases, which is expected to be maintained as a security deposit for the duration of the lease. In addition, we have restricted cash of $0.7 million as of September 30, 2022 for a grant issued by the Bill & Melinda Gates Foundation (“BMGF”). The restriction is expected to lapse as we fulfill our obligations in the grant agreement with BMGF.

The nature of the Company’s cash requirements has not changed significantly during the three and nine months ended September 30, 2022. We have entered into material contractual obligations with third parties for facility lease arrangements for office space and inventory supply agreements. As of September 30, 2022, we had fixed lease payment obligations of $41.1 million, with $3.1 million payable within 12 months. As of September 30, 2022, we had fixed purchase obligations of $71.2 million, with $67.9 million payable within 12 months. We expect to pay for approximately 40% of the fixed purchase obligations payable within the next 12 months using vendor advances.

As of September 30, 2022, we had no obligations, assets or liabilities, which would be considered off-balance sheet arrangements.

Cash flows

Comparison of the period for the nine months ended September 30, 2022 and 2021

The following table summarizes our sources and uses of cash for the nine months ended September 30, 2022 and 2021:

(in thousands)

​ ​ ​ ​ ​ ​ ​ Nine months ended September 30, 2022 ​ ​ ​ ​ 2021
Net cash used in operating activities $(140,256) $(146,410)
Net cash used in investing activities ​ (91,298) ​ (319,769)
Net cash provided by financing activities ​ 2,744 ​ 563,299
Net (decrease) increase in cash, cash equivalents and restricted cash $(228,810) $97,120

Net cash used in operating activities

Net cash used in operating activities represents the cash receipts and disbursements related to our activities other than investing and financing activities. We expect cash provided by historical financing activities will continue to be our primary source of funds to support operating needs and capital expenditures for the foreseeable future.

Net cash used in operating activities decreased by $6.2 million, or 4.2%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. The decrease was driven by an $11.8 million decrease in net working capital cash usage partially offset by a $5.8 million increase in net loss adjusted for certain noncash items, primarily driven by the change in fair value of warrant liabilities and stock-based compensation expense. The decrease in net working capital cash usage was mainly due to the $15.2 million decrease in cash used by vendor advances, $8.4 million decrease in cash used by prepaid expenses and other assets, $7.4 million decrease in cash used by accrued purchase commitments and $3.6 million decrease in cash used by accounts receivable, partially offset by a $22.9 million increase in cash used by inventories.

Net cash used in investing activities

Net cash used in investing activities decreased by $228.5 million, or 71.4%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. The decrease was primarily due to a decrease of $240.8 million in purchases and sales of marketable securities. The decrease was partially offset by an increase in purchases of property and equipment of $12.4 million related to the Company’s new office space and additional investments into our software platform.

Net cash provided by financing activities

Net cash provided by financing activities decreased by $560.6 million, or 99.5%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. The decrease was primarily due to the non-recurrence of net proceeds from the Business Combination of $548.4 million and a $16.5 million decrease in option exercises, partially offset by the non-recurrence of the $4.4 million repayment of the Paycheck Protection Program loan.

Critical Accounting Policies and Significant Judgments and Estimates

Our management's discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about items that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, there have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, as amended.

Recently Adopted Accounting Pronouncements

The Company did not identify any significant recently issued accounting pronouncements that may potentially impact our financial position and results of operations.

Market risk

As filed, 1,451 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Interest Rate Risk

We did not have any floating rate debt as of September 30, 2022. Our cash and cash equivalents and marketable securities are comprised primarily of bank deposits, money market accounts and equity interests in mutual funds. The primary objective of our investments is the preservation of capital to fulfill liquidity needs. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of these investments, we do not expect cash flows to be affected to any significant degree by a sudden change in market interest rates.

Inflation Risk

We do not believe that inflation has had a material effect on our business, financial condition or results of operations, other than its impact on the general economy. Nonetheless, to the extent our costs are impacted by general inflationary pressures, we may not be able to fully offset such higher costs through price increases or manufacturing efficiencies. Our inability or failure to do so could harm our business, financial condition and results of operations.

Foreign Exchange Risk

We operate our business primarily within the United States and currently execute the majority of our transactions in U.S. dollars. We have not utilized hedging strategies with respect to such foreign exchange exposure. This limited foreign currency translation risk is not expected to have a material impact on our condensed consolidated financial statements.

Controls and procedures

As filed, 1,768 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2022.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 459 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our business, results of operations and financial condition are subject to various risks and uncertainties including the risk factors described under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, filed with the SEC on February 28, 2022, as amended on March 28, 2022 and April 19, 2022 (the “2021 Annual Report on Form 10-K”). There have been no material changes to the risk factors described in the 2021 Annual Report on Form 10-K.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-07-01 to 2022-09-30$19.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2022-01-01 to 2022-09-30$54.4mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2022-07-01 to 2022-09-30$8.6mus-gaap:CostOfRevenue
Cost of revenue9 months2022-01-01 to 2022-09-30$24.5mus-gaap:CostOfRevenue
Gross profit3 months2022-07-01 to 2022-09-30$11.0mus-gaap:GrossProfit
Gross profit9 months2022-01-01 to 2022-09-30$29.9mus-gaap:GrossProfit
Research and development3 months2022-07-01 to 2022-09-30$23.2mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2022-01-01 to 2022-09-30$70.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-07-01 to 2022-09-30−$46.0mus-gaap:OperatingIncomeLoss
Operating income9 months2022-01-01 to 2022-09-30−$144.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2022-07-01 to 2022-09-30$2.0kus-gaap:InterestExpense
Interest expense9 months2022-01-01 to 2022-09-30$2.0kus-gaap:InterestExpense
Income tax3 months2022-07-01 to 2022-09-30$27.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2022-01-01 to 2022-09-30$68.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-07-01 to 2022-09-30−$54.7mus-gaap:NetIncomeLoss
Net income9 months2022-01-01 to 2022-09-30−$135.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-07-01 to 2022-09-30−$0.27us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2022-01-01 to 2022-09-30−$0.68us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-07-01 to 2022-09-30−$0.27us-gaap:EarningsPerShareBasic
Basic EPS9 months2022-01-01 to 2022-09-30−$0.68us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-07-01 to 2022-09-30200,172,683 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2022-01-01 to 2022-09-30199,528,394 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2022-01-01 to 2022-09-30−$140.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2022-01-01 to 2022-09-30$16.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-09-30$193.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-09-30$372.5mus-gaap:AssetsCurrent
Total assetsAt period end2022-09-30$443.3mus-gaap:Assets
Current liabilitiesAt period end2022-09-30$45.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-09-30$99.6mus-gaap:Liabilities
Shareholders' equityAt period end2022-09-30$343.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-22-016291. Last ingested by Listed: Nov 14, 2026, 23:40 ET. Listed shows no prices and gives no investment advice.